ERBB2 and breast carcinoma: Notably, 16 primary tumor models derived from HER2-negative breast cancer patients, including tumors with heterogeneity in expression of estrogen receptors and progesterone receptors and histological subclass, showed regression upon treatment with the biparatopic ADC.